266 related articles for article (PubMed ID: 19191333)
21. Mutations in RYR1 in malignant hyperthermia and central core disease.
Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations.
Jungbluth H; Davis MR; Müller C; Counsell S; Allsop J; Chattopadhyay A; Messina S; Mercuri E; Laing NG; Sewry CA; Bydder G; Muntoni F
Neuromuscul Disord; 2004 Dec; 14(12):785-90. PubMed ID: 15564033
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia.
Schiemann AH; Paul N; Parker R; Pollock N; Bulger TF; Stowell KM
Anesth Analg; 2014 Feb; 118(2):375-380. PubMed ID: 24361844
[TBL] [Abstract][Full Text] [Related]
24. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
[TBL] [Abstract][Full Text] [Related]
25. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation.
Sato I; Wu S; Ibarra MC; Hayashi YK; Fujita H; Tojo M; Oh SJ; Nonaka I; Noguchi S; Nishino I
Neurology; 2008 Jan; 70(2):114-22. PubMed ID: 17538032
[TBL] [Abstract][Full Text] [Related]
26. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores.
Monnier N; Marty I; Faure J; Castiglioni C; Desnuelle C; Sacconi S; Estournet B; Ferreiro A; Romero N; Laquerriere A; Lazaro L; Martin JJ; Morava E; Rossi A; Van der Kooi A; de Visser M; Verschuuren C; Lunardi J
Hum Mutat; 2008 May; 29(5):670-8. PubMed ID: 18253926
[TBL] [Abstract][Full Text] [Related]
27. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
[TBL] [Abstract][Full Text] [Related]
28. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
Broman M; Islander G; Müller CR; Ranklev-Twetman E
Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
[TBL] [Abstract][Full Text] [Related]
29. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases.
Broman M; Gehrig A; Islander G; Bodelsson M; Ranklev-Twetman E; Rüffert H; Müller CR
Br J Anaesth; 2009 May; 102(5):642-9. PubMed ID: 19346234
[TBL] [Abstract][Full Text] [Related]
30. Identification and Functional Analysis of RYR1 Variants in a Family with a Suspected Myopathy and Associated Malignant Hyperthermia.
Schiemann AH; Roesl C; Pollock N; Langton E; Bulger T; Stowell KM
J Neuromuscul Dis; 2020; 7(1):51-60. PubMed ID: 31903994
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
[TBL] [Abstract][Full Text] [Related]
32. Central core disease is due to RYR1 mutations in more than 90% of patients.
Wu S; Ibarra MC; Malicdan MC; Murayama K; Ichihara Y; Kikuchi H; Nonaka I; Noguchi S; Hayashi YK; Nishino I
Brain; 2006 Jun; 129(Pt 6):1470-80. PubMed ID: 16621918
[TBL] [Abstract][Full Text] [Related]
33. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis.
Broman M; Heinecke K; Islander G; Schuster F; Glahn K; Bodelsson M; Treves S; Müller C
Anesth Analg; 2011 Nov; 113(5):1120-8. PubMed ID: 21965348
[TBL] [Abstract][Full Text] [Related]
34. Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.
Hoppe K; Hack G; Lehmann-Horn F; Jurkat-Rott K; Wearing S; Zullo A; Carsana A; Klingler W
Sci Rep; 2016 Sep; 6():33372. PubMed ID: 27646467
[TBL] [Abstract][Full Text] [Related]
35. Identification of functional type 1 ryanodine receptors in human dendritic cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Ohshima S; Mizukami S; Ichihara Y; Kikuchi H; Matsushita S
Biochem Biophys Res Commun; 2007 Oct; 362(2):510-5. PubMed ID: 17707769
[TBL] [Abstract][Full Text] [Related]
36. Structural determinants of 4-chloro-m-cresol required for activation of ryanodine receptor type 1.
Jacobson AR; Moe ST; Allen PD; Fessenden JD
Mol Pharmacol; 2006 Jul; 70(1):259-66. PubMed ID: 16601083
[TBL] [Abstract][Full Text] [Related]
37. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.
Treves S; Jungbluth H; Muntoni F; Zorzato F
Curr Opin Pharmacol; 2008 Jun; 8(3):319-26. PubMed ID: 18313359
[TBL] [Abstract][Full Text] [Related]
38. [Malignant hyperthermia--a hereditary and potentially life-threatening condition].
Haugen T; Toft M; Müller CR; Aasly J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2792-4. PubMed ID: 16244682
[TBL] [Abstract][Full Text] [Related]
39. Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia.
Schiemann AH; Dürholt EM; Pollock N; Stowell KM
Br J Anaesth; 2013 Jan; 110(1):122-7. PubMed ID: 23035052
[TBL] [Abstract][Full Text] [Related]
40. Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms.
Duarte ST; Oliveira J; Santos R; Pereira P; Barroso C; Conceição I; Evangelista T
Muscle Nerve; 2011 Jul; 44(1):102-8. PubMed ID: 21674524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
